Capital Management Associates (New York)’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Capital Management Associates (New York)’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-5,000	Closed	-$781K	–	143
2014 Q3	$781K	Sell	5,000 -3,000	-38%	-$435K	1.18%	15
2014 Q2	$987K	Sell	8,000 -2,000	-20%	-$221K	1.44%	6
2014 Q1	$1.04M	Hold	10,000	–	–	1.5%	6
2013 Q4	$899K	Hold	10,000	–	–	1.33%	13
2013 Q3	$669K	Hold	10,000	–	–	1.03%	28
2013 Q2	$661K	Buy	+10,000	New	+$572K	1.08%	23

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Management Associates (New York)'s SLXP Position: Q4 2014 in Review

Capital Management Associates (New York) sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 5,000 shares — an estimated $781K sold.

Capital Management Associates (New York) first reported a position in SLXP in Q2 2013 and held it in 6 quarters. The position peaked at $1.04M in Q1 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

Capital Management Associates (New York) reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
Capital Management Associates (New York) sold 5,000 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $781K.
Capital Management Associates (New York) first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 6 quarters.
Capital Management Associates (New York)'s SALIX PHARMACEUTICALS LTD DEL position peaked at $1.04M in Q1 2014.
346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Capital Management Associates (New York)'s 13F filing for Q4 2014, filed 12 Feb 2015.